

Karl-Friedrich Becker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5650811/publications.pdf>

Version: 2024-02-01

131
papers

8,844
citations

47006

47
h-index

45317

90
g-index

137
all docs

137
docs citations

137
times ranked

13121
citing authors

#	ARTICLE	IF	CITATIONS
1	Stakeholder engagement to ensure the sustainability of biobanks: a survey of potential users of biobank services. <i>European Journal of Human Genetics</i> , 2021, , .	2.8	8
2	10th Anniversary of the European Association for Predictive, Preventive and Personalised (3P) Medicine – EPMA World Congress Supplement 2020. <i>EPMA Journal</i> , 2020, 11, 1-133.	6.1	34
3	Epidemiologic Risk Factors in a Comparison of a Barrett Esophagus Registry (BarrettNET) and a Case – Control Population in Germany. <i>Cancer Prevention Research</i> , 2020, 13, 377-384.	1.5	12
4	Oncogenic Linear Collagen VI of Invasive Breast Cancer Is Induced by CCL5. <i>Journal of Clinical Medicine</i> , 2020, 9, 991.	2.4	13
5	Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2019, 121, 1050-1057.	6.4	11
6	Pre-analytical processes in medical diagnostics: New regulatory requirements and standards. <i>New Biotechnology</i> , 2019, 52, 121-125.	4.4	35
7	BarrettNET – a prospective registry for risk estimation of patients with Barrett's esophagus to progress to adenocarcinoma. <i>Ecological Management and Restoration</i> , 2019, 32, .	0.4	7
8	PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4018-4018.	1.6	6
9	Lysate Preparation for Reverse Phase Protein Arrays. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1188, 21-30.	1.6	2
10	Quality Matters: 2016 Annual Conference of the National Infrastructures for Biobanking. <i>Biopreservation and Biobanking</i> , 2017, 15, 270-276.	1.0	26
11	Federated Biobanking with Corporate Service Unit: The Munich Biobank Alliance Blueprint. <i>Biopreservation and Biobanking</i> , 2017, 15, 75-79.	1.0	0
12	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2017, 32, 185-203.e13.	16.8	1,428
13	Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients. <i>Oncotarget</i> , 2017, 8, 97851-97861.	1.8	30
14	Prognostic value of the autophagy markers LC3 and p62/SQSTM1 in early-stage non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 39544-39555.	1.8	93
15	Reverse Phase Protein Arrays – Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use. <i>Microarrays (Basel, Switzerland)</i> , 2015, 4, 98-114.	1.4	61
16	Quantitative and integrated proteome and microRNA analysis of endothelial replicative senescence. <i>Journal of Proteomics</i> , 2015, 126, 12-23.	2.4	25
17	Using tissue samples for proteomic studies – Critical considerations. <i>Proteomics - Clinical Applications</i> , 2015, 9, 257-267.	1.6	15
18	Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues. <i>Laboratory Investigation</i> , 2015, 95, 561-571.	3.7	30

#	ARTICLE	IF	CITATIONS
19	Recent progress in protein profiling of clinical tissues for next-generation molecular diagnostics. Expert Review of Molecular Diagnostics, 2015, 15, 1277-1292.	3.1	6
20	Expression Patterns of Snail1, E-Cadherin and N-Cadherin Proteins in the Developing Kidney and in Wilms's Tumor (Nephroblastoma). Rare Cancers and Therapy, 2014, 2, 1-9.	0.2	0
21	Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus. Cancers, 2014, 6, 1382-1393.	3.7	13
22	Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report. Molecular and Cellular Proteomics, 2014, 13, 1625-1643.	3.8	152
23	Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer. British Journal of Cancer, 2014, 110, 2081-2089.	6.4	82
24	Evaluation of colon cancer histomorphology: a comparison between formalin and PAXgene tissue fixation by an international ring trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 509-519.	2.8	24
25	Characterization of Signalling Pathways by Reverse Phase Protein Arrays. Methods in Molecular Biology, 2013, 1049, 285-299.	0.9	6
26	Delayed Times to Tissue Fixation Result in Unpredictable Global Phosphoproteome Changes. Journal of Proteome Research, 2013, 12, 4424-4434.	3.7	32
27	A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas. British Journal of Cancer, 2013, 109, 370-378.	6.4	30
28	The PAXgene® Tissue System Preserves Phosphoproteins in Human Tissue Specimens and Enables Comprehensive Protein Biomarker Research. PLoS ONE, 2013, 8, e60638.	2.5	27
29	The PI3K/Akt/mTOR Pathway Is Implicated in the Premature Senescence of Primary Human Endothelial Cells Exposed to Chronic Radiation. PLoS ONE, 2013, 8, e70024.	2.5	82
30	Variation in Cell Signaling Protein Expression May Introduce Sampling Bias in Primary Epithelial Ovarian Cancer. PLoS ONE, 2013, 8, e77825.	2.5	12
31	Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping. Clinical Cancer Research, 2012, 18, 6426-6435.	7.0	110
32	A New Technology for Stabilization of Biomolecules in Tissues for Combined Histological and Molecular Analyses. Journal of Molecular Diagnostics, 2012, 14, 458-466.	2.8	74
33	uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases. Translational Oncology, 2012, 5, 98-103.	3.7	29
34	Variability of Protein and Phosphoprotein Levels in Clinical Tissue Specimens during the Preanalytical Phase. Journal of Proteome Research, 2012, 11, 5748-5762.	3.7	54
35	Evidence of Prognostic Relevant Expression Profiles of Heat-Shock Proteins and Glucose-Regulated Proteins in Oesophageal Adenocarcinomas. PLoS ONE, 2012, 7, e41420.	2.5	25
36	Antibody validation by combining immunohistochemistry and protein extraction from formalin-fixed paraffin-embedded tissues. Histopathology, 2012, 60, E37-50.	2.9	20

#	ARTICLE	IF	CITATIONS
37	Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR. <i>Journal of Cellular Physiology</i> , 2012, 227, 204-212.	4.1	21
38	Common Protein Biomarkers Assessed by Reverse Phase Protein Arrays Show Considerable Intratumoral Heterogeneity in Breast Cancer Tissues. <i>PLoS ONE</i> , 2012, 7, e40285.	2.5	24
39	Reverse-Phase Protein Microarrays. , 2011, , 279-282.		0
40	Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues. <i>Journal of Cancer</i> , 2011, 2, 26-35.	2.5	21
41	Successful Protein Extraction from Over-Fixed and Long-Term Stored Formalin-Fixed Tissues. <i>PLoS ONE</i> , 2011, 6, e16353.	2.5	50
42	Discovery of New Molecular Subtypes in Oesophageal Adenocarcinoma. <i>PLoS ONE</i> , 2011, 6, e23985.	2.5	24
43	Histological Assessment of PAXgene Tissue Fixation and Stabilization Reagents. <i>PLoS ONE</i> , 2011, 6, e27704.	2.5	70
44	Protein Microarray-based Comparison of HER2, Estrogen Receptor, and Progesterone Receptor Status in Core Biopsies and Surgical Specimens From FFPE Breast Cancer Tissues. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011, 19, 300-305.	1.2	22
45	“Liquid Morphology” <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011, 19, 1-9.	1.2	18
46	The HOPE fixation technique - a promising alternative to common prostate cancer biobanking approaches. <i>BMC Cancer</i> , 2011, 11, 511.	2.6	27
47	Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis. <i>Journal of Pathology</i> , 2011, 223, 54-63.	4.5	38
48	Use of Formalin-Fixed and Paraffin-Embedded Tissues for Diagnosis and Therapy in Routine Clinical Settings. <i>Methods in Molecular Biology</i> , 2011, 785, 109-122.	0.9	33
49	Producing Reverse Phase Protein Microarrays from Formalin-Fixed Tissues. <i>Methods in Molecular Biology</i> , 2011, 785, 123-140.	0.9	15
50	Comparison of Formalin-Free Tissue Fixatives: A Proteomic Study Testing Their Application for Routine Pathology and Research. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 744-752.	2.5	39
51	One-Dimensional Sodium-Dodecyl-Sulfate (SDS) Polyacrylamide Gel Electrophoresis. , 2011, , 261-264.		0
52	Interaction of Snail and p38 mitogen-activated protein kinase results in shorter overall survival of ovarian cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 705-713.	2.8	30
53	Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays. <i>Journal of Cellular Physiology</i> , 2010, 225, 364-370.	4.1	26
54	MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. <i>Endocrine-Related Cancer</i> , 2010, 17, 771-783.	3.1	135

#	ARTICLE	IF	CITATIONS
55	UPA and PAI-1 Analysis from Fixed Tissues – New Perspectives for a Known Set of Predictive Markers. <i>Current Medicinal Chemistry</i> , 2010, 17, 4370-4377.	2.4	23
56	Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. <i>European Journal of Cancer</i> , 2010, 46, 47-55.	2.8	59
57	Proteomic Analysis of PAXgene-Fixed Tissues. <i>Journal of Proteome Research</i> , 2010, 9, 5188-5196.	3.7	67
58	Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 3035.	3.0	195
59	Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. <i>Journal of Cell Biology</i> , 2009, 184, 399-408.	5.2	140
60	Activation of epidermal growth factor receptor results in Snail protein but not mRNA overexpression in endometrial cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 3858-3867.	3.6	29
61	Transcription factors Snail, Slug, Twist, and SIP1 in spindle cell carcinoma of the head and neck. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 549-555.	2.8	43
62	Precise measurement of the E-cadherin repressor Snail in formalin-fixed endometrial carcinoma using protein lysate microarrays. <i>Clinical and Experimental Metastasis</i> , 2008, 25, 679-683.	3.3	16
63	A case of multiple diffuse gastric carcinoma with regional expression of mutant E-cadherin. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 581-583.	2.8	1
64	Cadherin–catenin complex and transcription factor Snail-1 in spindle cell carcinoma of the head and neck. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 267-274.	2.8	49
65	Guided protein extraction from formalin-fixed tissues for quantitative multiplex analysis avoids detrimental effects of histological stains. <i>Proteomics - Clinical Applications</i> , 2008, 2, 737-743.	1.6	28
66	Enhanced Activation of Epidermal Growth Factor Receptor Caused by Tumor-Derived E-Cadherin Mutations. <i>Cancer Research</i> , 2008, 68, 707-714.	0.9	72
67	The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. <i>British Journal of Cancer</i> , 2008, 98, 489-495.	6.4	117
68	Extraction of Phosphorylated Proteins from Formalin-Fixed Cancer Cells and Tissues. <i>The Open Pathology Journal</i> , 2008, 2, 46-52.	1.0	12
69	Tumor-Associated E-Cadherin Mutations Affect Binding to the Killer Cell Lectin-Like Receptor G1 in Humans. <i>Journal of Immunology</i> , 2007, 179, 1022-1029.	0.8	56
70	The inhibition of Wnt/ β 2-catenin signalling by 1 α ,25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells. <i>Endocrine-Related Cancer</i> , 2007, 14, 141-151.	3.1	89
71	The E-cadherin Repressor Snail Plays a Role in Tumor Progression of Endometrioid Adenocarcinomas. <i>Diagnostic Molecular Pathology</i> , 2007, 16, 222-228.	2.1	62
72	Analysis of the E-Cadherin Repressor Snail in Primary Human Cancers. <i>Cells Tissues Organs</i> , 2007, 185, 204-212.	2.3	120

#	ARTICLE	IF	CITATIONS
73	Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. <i>Journal of Pathology</i> , 2007, 211, 370-378.	4.5	174
74	Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. <i>Journal of Pathology</i> , 2007, 211, 507-515.	4.5	157
75	Expression of E-cadherin and its repressor Snail in placental tissue of normal, preeclamptic and HELLP pregnancies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 195-202.	2.8	50
76	Tumor specificity and in vivo targeting of an antibody against exon 9 deleted E-cadherin in gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 987-994.	2.5	0
77	The antibody 2B4 directed against the Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV association of human cancers. <i>Journal of Pathology</i> , 2006, 209, 430-435.	4.5	26
78	Expression and nuclear localization of Snail, an E-cadherin repressor, in adenocarcinomas of the upper gastrointestinal tract. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 277-287.	2.8	72
79	Clinical Proteomics: New Trends for Protein Microarrays. <i>Current Medicinal Chemistry</i> , 2006, 13, 1831-1837.	2.4	32
80	Snail and Slug Play Distinct Roles during Breast Carcinoma Progression. <i>Clinical Cancer Research</i> , 2006, 12, 5395-5402.	7.0	230
81	Cutting Edge: Identification of E-Cadherin as a Ligand for the Murine Killer Cell Lectin-Like Receptor G1. <i>Journal of Immunology</i> , 2006, 176, 1311-1315.	0.8	138
82	Cell death triggered by alpha-emitting ²¹³ Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 274-285.	6.4	33
83	Noninvasive Visualization of the Activated α _v β ₃ Integrin in Cancer Patients by Positron Emission Tomography and [¹⁸ F]Galacto-RGD. <i>PLoS Medicine</i> , 2005, 2, e70.	8.4	443
84	11 Role of Immunohistochemical Expression of E-Cadherin in Diffuse-Type Gastric Cancer. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2005, 4, 169-175.	0.0	0
85	Molecular medicine of gastric adenocarcinomas. <i>Expert Reviews in Molecular Medicine</i> , 2005, 7, 1-13.	3.9	7
86	E-Cadherin expression in Sporadic Gastric cancer from Mexico: Exon 8 and 9 deletions are infrequent events associated with poor survival. <i>Human Pathology</i> , 2005, 36, 29-35.	2.0	30
87	Effect of Wild-Type and Mutant E-Cadherin on Cell Proliferation and Responsiveness to the Chemotherapeutic Agents Cisplatin, Etoposide, and 5-Fluorouracil. <i>Oncology</i> , 2004, 66, 150-159.	1.9	19
88	Tumor-associated E-cadherin mutations do not induce Wnt target gene expression, but affect E-cadherin repressors. <i>Laboratory Investigation</i> , 2004, 84, 1372-1386.	3.7	16
89	Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. <i>Modern Pathology</i> , 2004, 17, 579-587.	5.5	76
90	Pathology of upper gastrointestinal malignancies. <i>Seminars in Oncology</i> , 2004, 31, 465-475.	2.2	40

#	ARTICLE	IF	CITATIONS
91	Neoexpression of Nâ€cadherin in Eâ€cadherin positive colon cancers. International Journal of Cancer, 2004, 111, 711-719.	5.1	62
92	Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma. International Journal of Cancer, 2003, 104, 60-65.	5.1	34
93	Comparison of the Radiotoxicity of Two Alpha-Particle-Emitting Immunoconjugates, Terbium-149 and Bismuth-213, Directed against a Tumor-Specific, Exon 9 Deleted (d9) E-Cadherin Adhesion Protein. Radiation Research, 2003, 159, 612-620.	1.5	29
94	Molecular Analysis of Gene Expression in Tumor Pathology. Advances in Experimental Medicine and Biology, 2003, 532, 19-26.	1.6	1
95	Molecular Mechanisms of Carcinogenesis in Gastric Cancer. Recent Results in Cancer Research, 2003, 162, 65-72.	1.8	22
96	Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody. Clinical Cancer Research, 2003, 9, 3922S-8S.	7.0	19
97	Differential Expression of the Epithelial-Mesenchymal Transition Regulators Snail, SIP1, and Twist in Gastric Cancer. American Journal of Pathology, 2002, 161, 1881-1891.	3.8	526
98	Motility Enhancement by Tumor-Derived Mutant E-Cadherin Is Sensitive to Treatment with Epidermal Growth Factor Receptor and Phosphatidylinositol 3-Kinase Inhibitors. Experimental Cell Research, 2002, 276, 129-141.	2.6	20
99	CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. International Journal of Cancer, 2002, 101, 196-197.	5.1	50
100	Functional allelic loss detected at the protein level in archival human tumours using allele-specific E-cadherin monoclonal antibodies. Journal of Pathology, 2002, 197, 567-574.	4.5	24
101	Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers. Oncogene, 2002, 21, 4646-4662.	5.9	58
102	Magenkarzinom. , 2002, , 165-185.		0
103	Single amino acid substitutions in conserved extracellular domains of E-cadherin differ in their functional consequences 1 Edited by M. Yaniv. Journal of Molecular Biology, 2001, 314, 445-454.	4.2	43
104	Gastric adenocarcinoma: pathomorphology and molecular pathology. Journal of Cancer Research and Clinical Oncology, 2001, 127, 207-216.	2.5	120
105	Mutant Cell Surface Receptors as Targets for Individualized Cancer Diagnosis and Therapy. Current Cancer Drug Targets, 2001, 1, 121-128.	1.6	7
106	Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. Cancer Research, 2001, 61, 2804-8.	0.9	43
107	Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours. , 2000, 191, 162-169.		20
108	The use of molecular biology in diagnosis and prognosis of gastric cancer. Surgical Oncology, 2000, 9, 5-11.	1.6	82

#	ARTICLE	IF	CITATIONS
109	Tumor-Derived Mutated E-Cadherin Influences β -Catenin Localization and Increases Susceptibility to Actin Cytoskeletal Changes Induced by Pervanadate. <i>Cell Adhesion and Communication</i> , 2000, 7, 391-408.	1.7	33
110	Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. <i>Oncogene</i> , 1999, 18, 4301-4312.	5.9	187
111	Loss of immunohistochemical E-cadherin expression in colon cancer is not due to structural gene alterations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1999, 434, 489-495.	2.8	35
112	Identification of eleven novel tumor-associated e-cadherin mutations. <i>Human Mutation</i> , 1999, 13, 171-171.	2.5	31
113	Functional loss of E-cadherin and cadherin-11 alleles on chromosome 16q22 in colonic cancer. , 1999, 187, 530-534.		19
114	Diffuse Type Gastric and Lobular Breast Carcinoma in a Familial Gastric Cancer Patient with an E-Cadherin Germline Mutation. <i>American Journal of Pathology</i> , 1999, 155, 337-342.	3.8	267
115	Analysis of E-Cadherin in Diffuse-Type Gastric Cancer Using a Mutation-Specific Monoclonal Antibody. <i>American Journal of Pathology</i> , 1999, 155, 1803-1809.	3.8	71
116	Rapid Detection of Mutated E-Cadherin in Peritoneal Lavage Specimens From Patients With Diffuse-Type Gastric Carcinoma. <i>Diagnostic Molecular Pathology</i> , 1999, 8, 59-70.	2.1	39
117	Mutations of the human E-cadherin (CDH1) gene. <i>Human Mutation</i> , 1998, 12, 226-237.	2.5	504
118	Efficiency of Single-cell Polymerase Chain Reaction from Stained Histologic Slides and Integrity of DNA in Archival Tissue. <i>Diagnostic Molecular Pathology</i> , 1998, 7, 127.	2.1	0
119	Efficiency of Single-cell Polymerase Chain Reaction from Stained Histologic Slides and Integrity of DNA in Archival Tissue. <i>Diagnostic Molecular Pathology</i> , 1997, 6, 292-297.	2.1	17
120	Cut out or poke inâ€”the key to the world of single genes: laser micromanipulation as a valuable tool on the look-out for the origin of disease. <i>Genetic Analysis, Techniques and Applications</i> , 1997, 14, 1-8.	1.5	61
121	Laser-assisted preparation of single cells from stained histological slides for gene analysis. <i>Histochemistry and Cell Biology</i> , 1997, 108, 447-451.	1.7	47
122	Non-radioactive protein truncation test (nrPTT) for rapid detection of gene mutations. <i>Trends in Genetics</i> , 1996, 12, 250.	6.7	3
123	No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. <i>Cancer Research</i> , 1996, 56, 49-52.	0.9	89
124	Single nucleotide polymorphisms in the human E-cadherin gene. <i>Human Genetics</i> , 1995, 96, 739-740.	3.8	22
125	Frequent Somatic Allelic Inactivation of the E-cadherin Gene in Gastric Carcinomas. <i>Journal of the National Cancer Institute</i> , 1995, 87, 1082-1084.	6.3	49
126	Microsatellite instability in adenocarcinomas of the upper gastrointestinal tract. Relation to clinicopathological data and family history. <i>American Journal of Pathology</i> , 1995, 147, 593-600.	3.8	67

#	ARTICLE	IF	CITATIONS
127	Exon skipping in the E-cadherin gene transcript in metastatic human gastric carcinomas. <i>Human Molecular Genetics</i> , 1993, 2, 803-804.	2.9	98
128	New Mechanisms of Hormone Secretion: MDR-Like Gene Products as Extrusion Pumps for Hormones?. <i>Hormone and Metabolic Research</i> , 1992, 24, 210-213.	1.5	29
129	The multidrug-resistance gene MDR1 is expressed in human glial tumors. <i>Acta Neuropathologica</i> , 1991, 82, 516-519.	7.7	67
130	Regulatory structures of gene expression, DNA-replication and DNA-rearrangement in macronuclear genes of <i>Stylonychia lemnae</i> , a hypotrichous ciliate. <i>European Journal of Protistology</i> , 1989, 25, 158-167.	1.5	17
131	E-cadherin. <i>The AFCS-nature Molecule Pages</i> , 0, , .	0.2	1